B7-2基因工程抗体的制备及体内外抗B淋巴瘤作用研究  

Preparation of B7-2 Genetic Engineering Antibody and Studying of Anti-B lymphoma Effect in vivo and vitro

作　　者：刘玉华[1] 孙杰[1] 陈明心[1] 郭静雅[1] 胡玲玲[1] 王艳茹[1] 陈昌友[1] 高增燕[1] 朱晓燕[1] 邱玉华[1] 

机构地区：[1]苏州大学医学部免疫学系,江苏苏州215123

出　　处：《中山大学学报（自然科学版）》2010年第3期107-112,共6页Acta Scientiarum Naturalium Universitatis Sunyatseni

基　　金：科技部"重大新药创制"科技重大专项资助项目(2009ZX09103-705)

摘　　要：构建B7-2人-鼠嵌合抗体基因表达质粒pIRES/ch3C8,经脂质体法转染真核表达细胞株CHO制备B7-2人-鼠嵌合抗体(命名为ch3C8)。该抗体能够识别人恶性B淋巴瘤细胞株Raji表面的B7-2分子并诱导其凋亡。ch3C8结构中来源于人Ig的Fc段可介导高效的ADCC及CDC效应。经ch3C8结合的Raji细胞接种于BALB/c裸鼠后的致瘤性消失。该抗体在B7-2相关肿瘤的生物治疗中具有潜在的应用价值。Gene expression plasmid pIRES/ch3C8 of B7-2 human-mouse chimeric antibody was constructed,eukaryotic cell line CHO was transfected with pIRES/ch3C8 by liposome method,and prepared B7-2 human-mouse chimeric antibody（named ch3C8）.It could recognize B7-2 molecule on Raji,which is a human malignant B lymphoma cell line,and induce apoptosis of Raji.In addition,the ADCC and CDC effect was effectively mediated with the Fc fragment of the ch3C8 which come from human Ig.It was further showed that Raji lost oncogenicity with ch3C8 treated,which inoculated BALB/c nude mouse.ch3C8 will have a potential application value on B7-2 related tumor biotherapy.

关 键 词：B7-2 嵌合抗体 淋巴瘤 凋亡 ADCC效应 CDC效应 

分 类 号：R392.11[医药卫生—免疫学]